Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study

Keyphrases

• Autoimmune Disease 100%
• COVID-19 Vaccination 100%
• Idiopathic Inflammatory Myopathies 100%
• Long-term Safety 100%
• COVID Vaccination 100%
• Adverse Events 55%
• Systemic Autoimmune Disorders 55%
• Systemic Inflammatory Response Syndrome 55%
• Healthy Controls 33%
• Comorbidity 22%
• Active Disease 22%
• Hospitalization 22%
• Vaccination 22%
• Delayed Onset 22%
• Regression Model 11%
• COVID-19 11%
• Absence of Evidence 11%
• Oxford-AstraZeneca 11%
• Clinical High Risk 11%
• Revaccination 11%
• Vaccine Hesitancy 11%
• BNT162b2 11%
• Long COVID-19 11%
• Rash 11%
• ChAdOx1 11%
• Pfizer 11%
• Self-reporting 11%
• E-survey 11%
• Major Adverse Events 11%
• NCoV 11%
• COVID-19 Vaccine Safety 11%
• Autoimmune 11%
• Inclusion Body Myositis 11%
• Vaccine Adverse Events 11%
• Disease Overlap 11%
• Autoimmune Comorbidity 11%
• Overlap Myositis 11%
• Close Monitoring 11%
• Disorder Control 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Autoimmune Disease 100%
• Myositis 100%
• Disease 69%
• Adverse Event 69%
• Comorbidity 20%
• COVID-19 Vaccine 10%
• Vaccine 10%
• Rash 10%
• Multiple Chronic Conditions 10%
• Inclusion Body Myositis 10%

Immunology and Microbiology

• Vaccine 10%